Financial Highlights
Financial Summary (Unaudited)
| Amounts in millions, except per share amounts |
2009 |
2008 |
2007 |
2006 |
2005 |
| Net Sales |
$79,029 |
$81,748 |
$74,832 |
$66,724 |
$55,292 |
| Operating Income |
16,123 |
16,637 |
15,003 |
12,916 |
10,026 |
| Net Earnings |
13,436 |
12,075 |
10,340 |
8,684 |
6,923 |
| Net Earnings Margin from Continuing Operations |
14.3% |
14.4% |
13.4% |
12.7% |
12.0% |
| Diluted Net Earnings per Common Share from Continuing Operations |
$ 3.58 |
$ 3.56 |
$ 2.96 |
$ 2.58 |
$ 2.43 |
| Diluted Net Earnings per Common Share |
4.26 |
3.64 |
3.04 |
2.64 |
2.53 |
| Dividends per Common Share |
1.64 |
1.45 |
1.28 |
1.15 |
1.03 |
Net Sales
| Net Sales (in billions of dollars) |
|
| 05 |
$55.3 |
| 06 |
$66.7 |
| 07 |
$74.8 |
| 08 |
$81.7 |
| 09 |
$79 |
Diluted Net Earnings
| Diluted Net Earnings (per common share) |
|
| 05 |
$2.53 |
| 06 |
$2.64 |
| 07 |
$3.04 |
| 08 |
$3.64 |
| 09 |
$4.26 |
Operating Cash Flow
| Operating Cash Flow (in billions of dollars) |
|
| 05 |
$8.6 |
| 06 |
$66.7 |
| 07 |
$74.8 |
| 08 |
$15.0 |
| 09 |
$14.9 |
Note: Previous period results have been amended to exclude the results of the Folgers coffee business from continuing operations. For more information refer to Note 12.
The content of this page has not been updated to be consistent with the Company’s current presentation of financial results, which reflects the results of the global pharmaceuticals business (divested 10/09) as discontinued operations. For more up-to-date information, please refer to P&G’s Form 8-K filed with the SEC on 29-Jan-2010.
